Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 17, Issue 6, 1998, Pages 447-453

  Tremolieres F ^a   De Kock, F ^b   Pluck, N ^c   Daniel, R ^c  

^a Hôpital de Mantes   (France)

^b Kugersdorp Private Hospital   (South Africa)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL PNEUMONIA; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HAEMOPHILUS INFLUENZAE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE; VERTIGO; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN; ANTI-INFECTIVE AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROQUINOLONES; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; MALE; MIDDLE AGED; NAPHTHYRIDINES; PENICILLINS; PNEUMONIA, BACTERIAL; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE;

EID: 0031751311     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100960050106     Document Type: Article

References (27)

1. Bates JH, Campbell GD, Barron AL, McCracken GA, Morgan PN, Moses EB, Davies CM: Microbial etiology of acute pneumonia in hospitalized patients. Chest (1992) 101:1005-1012
2. LaForce MF: Antibacterial therapy for lower respiratory tract infections in adults: a review. Clinical Infectious Diseases (1992) 14, Supplement 1:233-237
3. Rodnick JE, Gude JK: Diagnosis and antibiotic treatment of community-acquired pneumonia. Western Journal of Medicine (1991) 154:405-409
4. British Thoracic Society Research Committee and the Public Health Laboratory Research Service: The aetiology, management and outcome of severe community-acquired pneumonia in the intensive care unit. Respiratory Medicine (1992) 86:7-13
5. Fang G, Fine M, Orloff J, Arisumi D, Yu VL, Kapoor W, Grayston JT, Wang SP, Kohler R, Muder RR, Yee YC, Rihs JD, Vickers RM: New and emerging etiologies for community-acquired pneumonia with implications for therapy. Medicine (1990) 69:307-316
6. Bariffi F, Sanduzzi A, Ponticiella A: Epidemiology of lower respiratory tract infections. Journal of Chemotherapy (1995) 7:263-276
7. Pachon J, Prados MD, Capote F, Cuello JA, Garnacho J, Verano A: Severe community-acquired pneumonia: etiology, prognosis, and treatment. American Review of Respiratory Disease (1990) 142:369-373
8. Briggs-Gooding B, Jones RN: In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrobial Agents and Chemotherapy (1993) 37:349-353
9. Eliopoulos GM, Klimm K, Eliopoulos CT, Ferraro MJ, Moellering RC: In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrobial Agents and Chemotherapy (1993) 37:366-370
10. Gootz TD, Brighty KE, Anderson MR, Schmieder BJ, Haskell SL, Sutcliffe JA, Castaldi MJ, McGuirk PR: In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl)-naphthyridone antimicrobial. Diagnostic Microbiology and Infectious Disease (1994) 19:235-243
11. Appelbaum PC: Quinolone activity against anaerobes: microbiological aspects. Drugs (1995) 49, Supplement 2:76-80
12. Roblin PM, Kutlin A, Hammerschlag MR: In vitro activity of trovafloxacin against Chlamydia pneumoniae. Antimicrobial Agents and Chemotherapy (1997) 41:2033-2034
13. Kenny GE, Cartwright FD: Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219). Antimicrobial Agents and Chemotherapy (1996) 40:1048-1049
14. Edelstein PH, Edelstein MAC, Ren J, Polzer R, Gladue RP: Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. Antimicrobial Agents and Chemotherapy (1996) 40:314-319
15. Kim YS, Liu O, Chow LL, Tauber MG: Trovafloxacin in treatment of rabbits with experimental meningitis caused by high-level penicillin-resistant Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy (1997) 39:1186-1189
16. Paris M, Hickey SM, Trujillo M, Shelton S, McCracken GH: Evaluation of CP-99-219, a new fluoroquinolone, for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrobial Agents and Chemotherapy (1995) 39:1243-1246
17. Klugman KP, Wasas A: In-vitro activity of the fluoroquinolone CP-99,219 against penicillin-resistant Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy (1995) 36:873-874
18. Fine MJ, Smith DN, Singer DE: Hospitalization decision in patients with community-acquired pneumonia: a prospective cohort study. American Journal of Medicine (1990) 89:713-721
19. American Thoracic Society: Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial microbial therapy. American Reviews of Respiratory Disease (1993) 148:1414-1426
20. Trémolières D, DeKock A, Pluck N: Empirical treatment of nonsevere community-acquired pneumonia: still a difficult issue. European Respiratory Journal (1995) 8:1996-1998
21. Child J, Andrews J, Boswell F, Brenwald N, Wise R: The in-vitro activity of CP-99,219, a new napthyridone antimicrobial agent: a comparison with fluoroquinolone agents. Journal of Antimicrobial Chemotherapy (1995) 35:869-876
22. Pontani D, Washton H, Bouchillon S, Johnson J: Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin. European Journal of Clinical Microbiology & Infectious Diseases (1998) 17:413-419
23. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR: The effect of prescribed daily dose frequency on patient medication compliance. Archives of Internal Medicine (1990) 150:1881-1884
24. Gootz TD, Zaniewski R, Haskell S, Schmieder B, Tankovic J, Girard D, Courvalin P, Polzer RJ: Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrobial Agents and Chemotherapy (1996) 40:2691-2697
25. Barry AL, Brown SD, Fuchs PC: In-vitro selection of quinolone-resistant staphylococcal mutants by a single exposure to ciprofloxacin or trovafloxacin (CP-99,219). Journal of Antimicrobial Chemotherapy (1996) 38:324-327
26. Köhler T, Michéa-Hamzehpoor M, Plésiat P, Kahr AL, Pechère J-C: Differential selection of multidrug efflux systems of quinolones in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy (1997) 41:2540-2543
27. Vincent J, Teng R, Dogolo LC, Willavize SA, Friedman HL: Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady-state pharmacokinetics of theophylline in healthy volunteers. Journal of Antimicrobial Chemotherapy (1997) 35, Supplement B:75-80